Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system
Authors' conclusion
GLP-1RAs were notably associated with reports of impaired gastric emptying in the FAERS.
Study context
- Population
- Adverse event reports of impaired gastric emptying (IGE) in the US FDA Adverse Event Reporting System (FAERS), 2004 Q1 to 2024 Q1IGE cases, top 10 drugs
- Participants
- 1,982 participants
- Outcome
- Association between GLP-1RAs and impaired gastric emptying (IGE) reports
Methodological detailsdisproportionality analysis of the FAERS database, reporting odds ratio, logistic regression, Kaplan-Meier and Weibull shape parameter tests
- Disproportionality analysis of the FAERS database
- Reporting odds ratio
- Logistic regression
- Kaplan-Meier and Weibull shape parameter tests
Main finding
As reported in the abstract
GLP-1RAs among top 10 drugs linked to IGE reports
GLP-1RAs among top 10 drugs associated with IGE reports
5
Proportion of IGE cases accounted for by GLP-1RAs
49.5%
982/1982
Observational data: associations, not effects.
Further findings
Older age and IGE risk, dulaglutide
| OR (95% CI) | P value | ||
|---|---|---|---|
| Older ageLower IGE risk with older age | 0.97 (0.94–1.00) | P = 0.033 | |
| 0.512Odds ratio (log scale) |
Older age and IGE risk, semaglutide
| OR (95% CI) | P value | ||
|---|---|---|---|
| Older ageLower IGE risk with older age | 0.96 (0.94–0.97) | P = 0.001 | |
| 0.512Odds ratio (log scale) |
Higher weight and IGE risk, exenatide
| OR (95% CI) | P value | ||
|---|---|---|---|
| Higher weightLower IGE risk | 0.99 (0.98–1.00) | P = 0.033 | |
| 0.512Odds ratio (log scale) |
Male sex and IGE risk, exenatide
| OR (95% CI) | P value | ||
|---|---|---|---|
| Male sexLower IGE risk | 0.39 (0.20–0.68) | P = 0.033 | |
| 0.20.5125Odds ratio (log scale) |
Median time to IGE onset from initiation of therapy
- Median time to IGE onset from initiation of therapy: range of median onset times across GLP-1RAs
Weibull shape parameter β
- β <1 for all GLP-1RAs, indicating higher IGE risk early in treatment
Original publication
Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system. Br J Anaesth. Published 21 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →